Unlike other IP agreements, TRIPS have an effective enforcement mechanism. States can be disciplined by the WTO dispute settlement mechanism. In addition to the basic intellectual property standards set out in the TRIPS agreement, many nations have committed to bilateral agreements to adopt a higher level of protection. This collection of standards, known as TRIPS or TRIPS-Plus, can take many forms.  The general objectives of these agreements are: the conditions of the plus members, which impose standards beyond the trips, have also been examined.  These free trade agreements contain conditions that limit the ability of governments to introduce competition for generic drug manufacturers. In particular, the United States has been criticized for promoting protection far beyond the standards prescribed by the TRIPS. The U.S. free trade agreements with Australia, Morocco and Bahrain have expanded patentability by making patents available for new uses of known products.  The TRIPS agreement authorizes the granting of compulsory licences at the discretion of a country. The terms of trips plus in the U.S. Free Trade Agreement with Australia, Jordan, Singapore and Vietnam have limited the application of mandatory licences to emergencies, remedies for cartels and abuse of dominance, and cases of non-commercial public use.  A 2003 agreement relaxed domestic market requirements and allowed developing countries to export to other countries with national health problems until drug exports are part of a trade or industrial policy.
 Drugs exported under such regulations may be packaged or coloured differently to prevent them from affecting the markets of industrialized countries. The ON TRIPS agreement is a minimum model agreement that allows members to more broadly protect intellectual property protection on demand. Members are free to determine the appropriate method of transposing the provisions of the agreement into their own legal and practical order. Among these agreements, the ip rights trade (TRIPS) aspects are expected to have the greatest impact on the pharmaceutical sector and access to medicines. The TRIPS agreement has been in force since 1995 and is the most comprehensive multilateral IP agreement to date. The TRIPS agreement introduced global minimum standards for the protection and enforcement of almost all forms of intellectual property rights (IPRs), including patent rights. International agreements prior to TRIPS did not contain minimum patent standards. At the time negotiations began, more than 40 countries around the world did not grant patent protection for pharmaceuticals. The TRIPS agreement now requires all WTO members, with a few exceptions, to adapt their legislation to minimum standards of intellectual property protection. In addition, the TRIPS agreement introduced detailed obligations to respect intellectual property rights. With the TRIPS agreement, intellectual property rights have been integrated into the multilateral trading system for the first time and remains the most comprehensive multilateral IP agreement to date. In 2001, developing countries, fearing that developed countries had insisted on too narrow a reading of the TRIPS trip, launched a series of discussions that culminated in the Doha Declaration.
The Doha Declaration is a WTO DECLARATION that clarifies the scope of the TRIPS agreement, which states, for example, that TRIPS can and should be interpreted in light of the objective of « promoting access to medicines for all ». Since the TRIPS agreement came into force, it has been criticized by developing countries, scientists and non-governmental organizations.